Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Tesamorelin
EfficacyHigh
Studies8
Participants1,459
StatusAvailable

Tesamorelin

Growth Hormone-Releasing Hormone (1-44) amide

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

Tesamorelin binds to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, specifically on somatotroph cells. This binding activates adenylyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels, which stimulates the synthesis and release of endogenous growth hormone. The released growth hormone then binds to growth hormone receptors in adipose tissue, activating hormone-sensitive lipase and promoting lipolysis, particularly in visceral fat deposits.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Tesamorelin for Visceral Adiposity in HIV: FDA Registration Trials

Read
AIDS (2010)
N = 816
High Impact
15.2% reduction in visceral adipose tissue vs 4.6% placebo over 26 weeks
DOI: 10.1097/QAD.0b013e32833c1c80

Long-term Safety and Efficacy of Tesamorelin in HIV Lipodystrophy

Read
Journal of Acquired Immune Deficiency Syndromes (2012)
N = 398
High Impact
Sustained visceral fat reduction maintained over 104 weeks of treatment
DOI: 10.1097/QAI.0b013e31825aa898

Growth Hormone Response and Metabolic Effects of Tesamorelin

Read
Endocrinology and Metabolism (2011)
N = 245
Medium Impact
181% increase in IGF-1 levels with maintained growth hormone response
DOI: 10.1210/jc.2011-0482
Search PubMed for 'tesamorelin HIV lipodystrophy' for comprehensive peer-reviewed research on this FDA-approved GHRH analog.

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.